COVID-19-related research market cap changes in biopharma companies Feb 2020
In the wake of the novel coronavirus outbreak, the biopharmaceutical company with the highest market capitalization change of over nine billion dollars - in the given time range - was Gilead Sciences as they started phase three trials of their antiviral drug remdesivir for the treatment of COVID-19. This statistic depicts the market capitalization changes of select biopharmaceutical companies which are involved in R&D on the novel coronavirus to find treatments or vaccines, in regards to the period from January 20 to February 25, 2020.